Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 437695, 9 pages
http://dx.doi.org/10.1155/2015/437695
Review Article

The Inflammatory Actions of Coagulant and Fibrinolytic Proteases in Disease

Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, VIC 3010, Australia

Received 31 December 2014; Revised 2 March 2015; Accepted 16 March 2015

Academic Editor: Alex Kleinjan

Copyright © 2015 Michael Schuliga. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. H. Versteeg, J. W. M. Heemskerk, M. Levi, and P. H. Reitsma, “New fundamentals in hemostasis,” Physiological Reviews, vol. 93, no. 1, pp. 327–358, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Tucker and S. Idell, “Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury,” Seminars in Thrombosis and Hemostasis, vol. 39, no. 4, pp. 373–381, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. S. Wagers, R. J. Norton, L. M. Rinaldi, J. H. T. Bates, B. E. Sobel, and C. G. Irvin, “Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness,” Journal of Clinical Investigation, vol. 114, no. 1, pp. 104–111, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. P. W. Noble, C. E. Barkauskas, and D. Jiang, “Pulmonary fibrosis: patterns and perpetrators,” The Journal of Clinical Investigation, vol. 122, no. 8, pp. 2756–2762, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. B. Smith, “Fibrinogen, fibrin and the arterial wall,” European Heart Journal, vol. 16, supplement A, pp. 11–15, 1995. View at Google Scholar · View at Scopus
  6. H. Raghu and M. J. Flick, “Targeting the coagulation factor fibrinogen for arthritis therapy,” Current Pharmaceutical Biotechnology, vol. 12, no. 9, pp. 1497–1506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F. W. Schardt, B. Schmausser, and E. Bachmann, “Monoclonal antibodies for immunodetection of fibrin deposits on cancer cells,” Histology and Histopathology, vol. 28, no. 8, pp. 993–998, 2013. View at Google Scholar · View at Scopus
  8. L. M. Altrogge and D. Monard, “An assay for high-sensitivity detection of thrombin activity and determination of proteases activating or inactivating protease-activated receptors,” Analytical Biochemistry, vol. 277, no. 1, pp. 33–45, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Bhattacharjee, J. Ahamed, R. Pawlinski et al., “Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1,” Circulation Research, vol. 102, no. 4, pp. 457–464, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Majumdar, T. Tarui, B. Shi, N. Akakura, W. Ruf, and Y. Takada, “Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin α9β1,” Journal of Biological Chemistry, vol. 279, no. 36, pp. 37528–37534, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Wei, J. A. Eble, Z. Wang, J. A. Kreidberg, and H. A. Chapman, “Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1,” Molecular Biology of the Cell, vol. 12, no. 10, pp. 2975–2986, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Hu, C. Wu, W. M. Mars, and Y. Liu, “Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3821–3832, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. V. O. Millien, W. Lu, J. Shaw et al., “Cleavage of fibrinogen by proteinases elicits allergic responses through toll-like receptor 4,” Science, vol. 341, no. 6147, pp. 792–796, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. G. Stewart, Y. C. Xia, T. Harris, S. Royce, J. A. Hamilton, and M. Schuliga, “Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling,” British Journal of Pharmacology, vol. 170, no. 7, pp. 1421–1435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. B. N. Lambrecht and H. Hammad, “Asthma and coagulation,” The New England Journal of Medicine, vol. 369, no. 20, pp. 1964–1966, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. de Boer, C. J. Majoor, C. Van't Veer, E. H. D. Bel, and T. van der Poll, “Asthma and coagulation,” Blood, vol. 119, no. 14, pp. 3236–3244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. Campbell, K. A. Overmyer, C. H. Selzman, B. C. Sheridan, and A. S. Wolberg, “Contributions of extravascular and intravascular cells to fibrin network formation, structure, and stability,” Blood, vol. 114, no. 23, pp. 4886–4896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. F. Dvorak, D. R. Senger, A. M. Dvorak, V. S. Harvey, and J. McDonagh, “Regulation of extravascular coagulation by microvascular permeability,” Science, vol. 227, no. 4690, pp. 1059–1061, 1985. View at Publisher · View at Google Scholar · View at Scopus
  19. F. J. H. Brims, A. J. Chauhan, B. Higgins, and J. K. Shute, “Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids,” Thorax, vol. 64, no. 12, pp. 1037–1043, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Günther, P. Mosavi, C. Ruppert et al., “Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease,” Thrombosis and Haemostasis, vol. 83, no. 6, pp. 853–860, 2000. View at Google Scholar · View at Scopus
  21. C. J. Majoor, M. A. van de Pol, P. W. Kamphuisen et al., “Evaluation of coagulation activation after rhinovirus infection in patients with asthma and healthy control subjects: an observational study,” Respiratory Research, vol. 15, article 14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. J. Scotton, M. A. Krupiczojc, M. Königshoff et al., “Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury,” The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2550–2563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Carmassi, F. de Negri, M. Morale, K. Y. Song, and S. I. Chung, “Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis,” Seminars in Thrombosis and Hemostasis, vol. 22, no. 6, pp. 489–496, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. N. N. Jarjour and G. Enhorning, “Antigen-induced airway inflammation in atopic subjects generates dysfunction of pulmonary surfactant,” The American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 1, pp. 336–341, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Wagers, L. K. A. Lundblad, M. Ekman, C. G. Irvin, and J. H. T. Bates, “The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?” Journal of Applied Physiology, vol. 96, no. 6, pp. 2019–2027, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. O. Sanchez-Pernaute, M. Filkova, A. Gabucio et al., “Citrullination enhances the pro-inflammatory response to fibrin in rheumatoid arthritis synovial fibroblasts,” Annals of the Rheumatic Diseases, vol. 72, no. 8, pp. 1400–1406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Kim and K. A. Hajjar, “Annexin II: a plasminogen-plasminogen activator co-receptor,” Frontiers in Bioscience, vol. 7, pp. d341–d348, 2002. View at Google Scholar · View at Scopus
  28. P. A. Madureira, A. P. Surette, K. D. Phipps, M. A. S. Taboski, V. A. Miller, and D. M. Waisman, “The role of the annexin A2 heterotetramer in vascular fibrinolysis,” Blood, vol. 118, no. 18, pp. 4789–4797, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H. C. Kwaan and B. McMahon, “The role of plasminogen-plasmin system in cancer,” Cancer Treatment and Research, vol. 148, pp. 43–66, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Del Rosso, F. Margheri, S. Serratì, A. Chillà, A. Laurenzana, and G. Fibbi, “The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation,” Current Pharmaceutical Design, vol. 17, no. 19, pp. 1924–1943, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. M. Swaisgood, E. L. French, C. Noga, R. H. Simon, and V. A. Ploplis, “The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system,” The American Journal of Pathology, vol. 157, no. 1, pp. 177–187, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. C. E. Stewart, H. S. Nijmeh, C. E. Brightling, and I. Sayers, “uPAR regulates bronchial epithelial repair in vitro and is elevated in asthmatic epithelium,” Thorax, vol. 67, no. 6, pp. 477–487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Schuliga, S. Langenbach, Y. C. Xia et al., “Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2,” The American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 5, pp. 751–758, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. Q. Li, Y. Laumonnier, T. Syrovets, and T. Simmet, “Plasmin triggers cytokine induction in human monocyte-derived macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1383–1389, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. W. P. Fay, N. Garg, and M. Sunkar, “Vascular functions of the plasminogen activation system,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1231–1237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. E. G. Levin and D. J. Loskutoff, “Comparative studies of the fibrinolytic activity of cultured vascular cells,” Thrombosis Research, vol. 15, no. 5-6, pp. 869–878, 1979. View at Publisher · View at Google Scholar · View at Scopus
  37. B. J. Bloom, A. J. Alario, and L. C. Miller, “Persistent elevation of fibrin D-dimer predicts longterm outcome in systemic juvenile idiopathic arthritis,” Journal of Rheumatology, vol. 36, no. 2, pp. 422–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. B. Weinberg, A. M. M. Pippen, and C. S. Greenberg, “Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis,” Arthritis and Rheumatism, vol. 34, no. 8, pp. 996–1005, 1991. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Yang and C. Y. Kuan, “Anti-tissue Plasminogen Activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation,” CNS Neuroscience & Therapeutics, 2014. View at Publisher · View at Google Scholar
  40. R. C. Chambers and C. J. Scotton, “Coagulation cascade proteinases in lung injury and fibrosis,” Proceedings of the American Thoracic Society, vol. 9, no. 3, pp. 96–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Shetty, A. Kumar, A. R. Johnson et al., “Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs,” The American Journal of Respiratory Cell and Molecular Biology, vol. 15, no. 1, pp. 78–87, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Olman, N. Mackman, C. L. Gladson, K. M. Moser, and D. J. Loskutoff, “Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse,” The Journal of Clinical Investigation, vol. 96, no. 3, pp. 1621–1630, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Nishiuma, T. H. Sisson, N. Subbotina, and R. H. Simon, “Localization of plasminogen activator activity within normal and injured lungs by in situ zymography,” The American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 5, pp. 552–558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Tjeldhorn, P. M. Sandset, K. Haugbro, and G. Skretting, “Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis,” Thrombosis Research, vol. 125, no. 3, pp. 230–234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. F. J. H. Brims, A. J. Chauhan, B. Higgins, and J. K. Shute, “Up-regulation of the extrinsic coagulation pathway in acute asthma—a case Study,” Journal of Asthma, vol. 47, no. 6, pp. 695–698, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Kowal, S. Zukowski, M. Moniuszko, and A. Bodzenta-Łukaszyk, “Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients,” Folia Histochemica et Cytobiologica, vol. 46, no. 2, pp. 193–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. Z. Ma, D. Paek, and C. K. Oh, “Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation,” Clinical and Experimental Allergy, vol. 39, no. 8, pp. 1136–1144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Xiao, Y.-P. Hsu, A. Ishizaka, T. Kirikae, and R. B. Moss, “Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation,” Chest, vol. 128, no. 4, pp. 2316–2326, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Iwaki, T. Urano, and K. Umemura, “PAI-1, progress in understanding the clinical problem and its aetiology,” British Journal of Haematology, vol. 157, no. 3, pp. 291–298, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Schneider and M. Nesheim, “A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis,” The Journal of Biological Chemistry, vol. 279, no. 14, pp. 13333–13339, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Tripodi and P. M. Mannucci, “The coagulopathy of chronic liver disease,” The New England Journal of Medicine, vol. 365, no. 2, pp. 147–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. D. A. Tregouet, R. Schnabel, M. C. Alessi et al., “Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study,” Journal of Thrombosis and Haemostasis, vol. 7, no. 1, pp. 49–57, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Saibeni, B. Bottasso, L. Spina et al., “Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases,” The American Journal of Gastroenterology, vol. 99, no. 10, pp. 1966–1970, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. E. L. G. Pryzdial and G. E. Kessler, “Autoproteolysis or plasmin-mediated cleavage of factor Xaα exposes a plasminogen binding site and inhibits coagulation,” The Journal of Biological Chemistry, vol. 271, no. 28, pp. 16614–16620, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Talbot, S. C. Meixner, and E. L. G. Pryzdial, “Enhanced fibrinolysis by proteolysed coagulation factor Xa,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1804, no. 4, pp. 723–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Åberg, M. Johnell, M. Wickström, and A. Siegbahn, “Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1),” Thrombosis Research, vol. 127, no. 2, pp. 141–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. J. Bolton, C. A. McNulty, R. J. Thomas, C. R. A. Hewitt, and A. J. Wardlaw, “Expression of and functional responses to protease-activated receptors on human eosinophils,” Journal of Leukocyte Biology, vol. 74, no. 1, pp. 60–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. G. R. Stenton, O. Nohara, R. E. Déry et al., “Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 2, pp. 466–474, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Zhu, M. Bi, Y. Liu et al., “Thrombin promotes airway remodeling via protease-activated receptor-1 and transforming growth factor-β1 in ovalbumin-allergic rats,” Inhalation Toxicology, vol. 25, no. 10, pp. 577–586, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Colognato, J. R. Slupsky, M. Jendrach, L. Burysek, T. Syrovets, and T. Simmet, “Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells,” Blood, vol. 102, no. 7, pp. 2645–2652, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. D. A. Knight, S. Lim, A. K. Scaffidi et al., “Protease-activated receptors in human airways: upregulation of PAR-2 in respiratory epithelium from patients with asthma,” Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 797–803, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. P. F. Mercer, R. H. Johns, C. J. Scotton et al., “Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary Fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 5, pp. 414–425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. D. C. J. Howell, R. H. Johns, J. A. Lasky et al., “Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis,” The American Journal of Pathology, vol. 166, no. 5, pp. 1353–1365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Ortiz-Stern, X. Deng, N. Smoktunowicz, P. F. Mercer, and R. C. Chambers, “PAR-1-dependent and PAR-independent pro-inflammatory signaling in human lung fibroblasts exposed to thrombin,” Journal of Cellular Physiology, vol. 227, no. 11, pp. 3575–3584, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. O. P. Blanc-Brude, F. Archer, P. Leoni et al., “Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation,” Experimental Cell Research, vol. 304, no. 1, pp. 16–27, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. U. R. Pendurthi, M. Ngyuen, P. Andrade-Gordon, L. C. Petersen, and L. V. M. Rao, “Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 9, pp. 1421–1426, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Martorell, J. Martínez-González, C. Rodríguez, M. Gentile, O. Calvayrac, and L. Badimon, “Thrombin and protease-activated receptors (PARs) in atherothrombosis,” Thrombosis and Haemostasis, vol. 99, no. 2, pp. 305–315, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Kaufmann, S. Rahn, K. Pollrich et al., “Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4,” Journal of Cellular Physiology, vol. 211, no. 3, pp. 699–707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Xue, Y.-K. A. Chan, K. Shen et al., “Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 64, no. 1, pp. 88–98, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Kerschen, I. Hernandez, M. Zogg et al., “Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3167–3178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Cao, Y. Gao, Y. Li, T. M. Antalis, F. J. Castellino, and L. Zhang, “The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b,” The Journal of Clinical Investigation, vol. 120, no. 6, pp. 1971–1980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Laumonnier, T. Syrovets, L. Burysek, and T. Simmet, “Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes,” Blood, vol. 107, no. 8, pp. 3342–3349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. T. J. MacLeod, M. Kwon, N. R. Filipenko, and D. M. Waisman, “Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits. Characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin,” The Journal of Biological Chemistry, vol. 278, no. 28, pp. 25577–25584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Lin, C. Wu, and K. Hu, “Tissue plasminogen activator activates NF-kappaB through a pathway involving annexin A2/CD11b and integrin-linked kinase,” Journal of the American Society of Nephrology, vol. 23, no. 8, pp. 1329–1338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. H. Lin, A. P. Liu, T. H. Smith, and J. Trejo, “Cofactoring and dimerization of proteinase-activated receptors,” Pharmacological Reviews, vol. 65, no. 4, pp. 1198–1213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. T. A. McEachron, R. Pawlinski, K. L. Richards, F. C. Church, and N. Mackman, “Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis,” Blood, vol. 116, no. 23, pp. 5037–5044, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Coutts, G. Chen, N. Stephens et al., “Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 280, no. 5, pp. L999–L1008, 2001. View at Google Scholar · View at Scopus
  78. E. Roztocil, S. M. Nicholl, I. I. Galaria, and M. G. Davies, “Plasmin-induced smooth muscle cell proliferation requires epidermal growth factor activation through an extracellular pathway,” Surgery, vol. 138, no. 2, pp. 180–186, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. E. I. Deryugina and J. P. Quigley, “Cell surface remodeling by plasmin: a new function for an old enzyme,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 564259, 21 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Schuliga, T. Harris, and A. G. Stewart, “Plasminogen activation by airway smooth muscle is regulated by type I collagen,” The American Journal of Respiratory Cell and Molecular Biology, vol. 44, no. 6, pp. 831–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. K. M. Austin, L. Covic, and A. Kuliopulos, “Matrix metalloproteases and PAR1 activation,” Blood, vol. 121, no. 3, pp. 431–439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Shetty, Y. P. Bhandary, S. K. Shetty et al., “Induction of tissue factor by urokinase in lung epithelial cells and in the lungs,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 12, pp. 1355–1366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Zhang, W. Xiao, Y. Jiang et al., “Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling,” Journal of International Medical Research, vol. 40, no. 3, pp. 976–985, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. D. Cook, C. M. De Nardo, E. L. Braine et al., “Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement,” Arthritis Research and Therapy, vol. 12, no. 2, article R37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Tang and X. Han, “The urokinase plasminogen activator system in breast cancer invasion and metastasis,” Biomedicine and Pharmacotherapy, vol. 67, no. 2, pp. 179–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. A. de Paulis, N. Montuori, N. Prevete et al., “Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2,” The Journal of Immunology, vol. 173, no. 9, pp. 5739–5748, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. A. M. Bakken, C. D. Protack, E. Roztocil, S. M. Nicholl, and M. G. Davies, “Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism,” Journal of Vascular Surgery, vol. 49, no. 5, pp. 1296–1303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. H. W. Smith and C. J. Marshall, “Regulation of cell signalling by uPAR,” Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 23–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Tarui, N. Akakura, M. Majumdar et al., “Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation,” Thrombosis and Haemostasis, vol. 95, no. 3, pp. 524–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. R. M. Senior, W. F. Skogen, G. L. Griffin, and G. D. Wilner, “Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B,” The Journal of Clinical Investigation, vol. 77, no. 3, pp. 1014–1019, 1986. View at Publisher · View at Google Scholar · View at Scopus
  91. D. L. Richardson, D. S. Pepper, and A. B. Kay, “Chemotaxis for human monocytes by fibrinogen derived peptides,” British Journal of Haematology, vol. 32, no. 4, pp. 507–513, 1976. View at Publisher · View at Google Scholar · View at Scopus
  92. T. J. Gross, K. J. Leavell, and M. W. Peterson, “CD11b/CD18 mediates the neutrophil chemotactic activity of fibrin degradation product D domain,” Thrombosis and Haemostasis, vol. 77, no. 5, pp. 894–900, 1997. View at Google Scholar · View at Scopus
  93. M. Naito, C. M. Stirk, E. B. Smith, and W. D. Thompson, “Smooth muscle cell outgrowth stimulated by fibrin degradation products: the potential role of fibrin fragment E in restenosis and atherogenesis,” Thrombosis Research, vol. 98, no. 2, pp. 165–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. S. C. Robson, E. G. Shephard, and R. E. Kirsch, “Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro,” British Journal of Haematology, vol. 86, no. 2, pp. 322–326, 1994. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Hamaguchi, Y. Morishita, I. Takahashi, M. Ogura, J. Takamatsu, and H. Saito, “FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line,” Blood, vol. 77, no. 1, pp. 94–100, 1991. View at Google Scholar · View at Scopus
  96. C. Jennewein, N. Tran, P. Paulus, P. Ellinghaus, J. A. Eble, and K. Zacharowski, “Novel aspects of fibrin(ogen) fragments during inflammation,” Molecular Medicine, vol. 17, no. 5-6, pp. 568–573, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. R. V. Lalla, M. L. Tanzer, and D. L. Kreutzer, “Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells,” Archives of Oral Biology, vol. 48, no. 4, pp. 263–271, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Gröger, W. Pasteiner, G. Ignatyev et al., “Peptide Bβ15-42 preserves endothelial barrier function in shock,” PLoS ONE, vol. 4, no. 4, Article ID e5391, 2009. View at Publisher · View at Google Scholar
  99. J. P. Roesner, P. Petzelbauer, A. Koch et al., “Bβ15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion,” Critical Care Medicine, vol. 37, no. 2, pp. 598–605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Doronin, J. W. Flatt, N. C. di Paolo et al., “Coagulation factor X activates innate immunity to human species C adenovirus,” Science, vol. 338, no. 6108, pp. 795–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. J. F. A. Swisher, N. Burton, S. M. Bacot, S. N. Vogel, and G. M. Feldman, “Annexin A2 tetramer activates human and murine macrophages through TLR4,” Blood, vol. 115, no. 3, pp. 549–558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. K. L. Allen, F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, and K. R. McCrae, “A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies,” Blood, vol. 119, no. 3, pp. 884–893, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. K.-L. He, G. Sui, H. Xiong et al., “Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2,” The Journal of Biological Chemistry, vol. 286, no. 17, pp. 15428–15439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. D. K. Ingawale, S. K. Mandlik, and S. S. Patel, “An emphasis on molecular mechanisms of anti-inflammatory effects and glucocorticoid resistance,” Journal of Complementary and Integrative Medicine, vol. 12, no. 1, pp. 1–13, 2015. View at Publisher · View at Google Scholar
  105. C. R. Keenan, S. Salem, E. R. Fietz, R. C. Gualano, and A. G. Stewart, “Glucocorticoid-resistant asthma and novel anti-inflammatory drugs,” Drug Discovery Today, vol. 17, no. 17-18, pp. 1031–1038, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Tran, D. J. Fernandes, M. Schuliga, T. Harris, L. Landells, and A. G. Stewart, “Stimulus-dependent glucocorticoid-resistance of GM-CSF production in human cultured airway smooth muscle,” British Journal of Pharmacology, vol. 145, no. 1, pp. 123–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. J. V. Bonacci, M. Schuliga, T. Harris, and A. G. Stewart, “Collagen impairs glucocorticoid actions in airway smooth muscle through integrin signalling,” British Journal of Pharmacology, vol. 149, no. 4, pp. 365–373, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Xie, K. Gao, L. Häkkinen, and H. S. Larjava, “Mice lacking β6 integrin in skin show accelerated wound repair in dexamethasone impaired wound healing model,” Wound Repair and Regeneration, vol. 17, no. 3, pp. 326–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. J. A. P. Spijkers-Hagelstein, S. M. Pinhanços, P. Schneider, R. Pieters, and R. W. Stam, “Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia,” Leukemia, vol. 27, no. 5, pp. 1063–1071, 2013. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Graff and S. Harder, “Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment,” Clinical Pharmacokinetics, vol. 52, no. 4, pp. 243–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. S. L. French, J. F. Arthur, H. A. Tran, and J. R. Hamilton, “Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent,” Blood Reviews, 2014. View at Publisher · View at Google Scholar
  112. D. Capodanno, D. L. Bhatt, S. Goto et al., “Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials,” Journal of Thrombosis and Haemostasis, vol. 10, no. 10, pp. 2006–2015, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Zhu, V. M. Gokhale, L. Szabo et al., “Identification of a novel inhibitor of urokinase-type plasminogen activator,” Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1348–1356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. I. Henneke, S. Greschus, R. Savai et al., “Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model,” The American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 6, pp. 611–619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Schmitt, N. Harbeck, N. Brünner et al., “Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1,” Expert Review of Molecular Diagnostics, vol. 11, no. 6, pp. 617–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. I. K. Lund, M. G. Rasch, S. Ingvarsen et al., “Inhibitory monoclonal antibodies against mouse proteases raised in Gene-Deficient mice block proteolytic functions in vivo,” Frontiers in Pharmacology, vol. 3, article 122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. K. A. Botkjaer, S. Fogh, E. C. Bekes et al., “Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies,” Biochemical Journal, vol. 438, no. 1, pp. 39–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. X.-Q. Wang, K. Bdeir, S. Yarovoi, D. B. Cines, W. Fang, and E. Abraham, “Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury,” The Journal of Immunology, vol. 177, no. 8, pp. 5550–5557, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. J. Inokuchi, N. Narula, D. S. Yee et al., “Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells,” International Journal of Cancer, vol. 124, no. 1, pp. 68–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. M. R. Sharma, V. Rothman, G. P. Tuszynski, and M. C. Sharma, “Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action,” Experimental and Molecular Pathology, vol. 81, no. 2, pp. 136–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Sharma, M. R. Blackman, and M. C. Sharma, “Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model,” Experimental and Molecular Pathology, vol. 92, no. 1, pp. 175–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. L. Zheng and E. M. Jaffee, “Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy,” OncoImmunology, vol. 1, no. 1, pp. 112–114, 2012. View at Publisher · View at Google Scholar · View at Scopus